277 related articles for article (PubMed ID: 12959773)
21. [Five-year outcome of a new combination chemotherapy with CEA/ABVD for advanced Hodgkin's disease with poor prognosis].
Kharchenko VP; Datsenko PV; Panyshin GA; Sotnikov VM; Mel'nik IuD
Vopr Onkol; 2006; 52(5):531-7. PubMed ID: 17168361
[TBL] [Abstract][Full Text] [Related]
22. Autoimmune hemolytic anemia and classical Hodgkin lymphoma: a case report and literature review.
Feng Q; Zak D; Daya R
Clin Adv Hematol Oncol; 2012 Apr; 10(4):270-6. PubMed ID: 22706493
[No Abstract] [Full Text] [Related]
23. Uncommon presentations of Hodgkin's disease. Case 3. Hodgkin's disease: rectal presentation.
Simpson L; Taylor S; Piotrowski A
J Clin Oncol; 2004 Jan; 22(1):196-8. PubMed ID: 14701784
[No Abstract] [Full Text] [Related]
24. Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult.
Lee SM; Buchler T; Bomanji J; Ramsay A; Edwards SG
AIDS; 2008 Jan; 22(1):159-60. PubMed ID: 18090408
[No Abstract] [Full Text] [Related]
25. Hodgkin's disease in Indian children: outcome with chemotherapy alone.
Arya LS; Dinand V; Thavaraj V; Bakhshi S; Dawar R; Rath GK; Singh R; Vats TS
Pediatr Blood Cancer; 2006 Jan; 46(1):26-34. PubMed ID: 16161019
[TBL] [Abstract][Full Text] [Related]
26. Marathon running during chemotherapy: where are the limits?
Dimeo FC
Onkologie; 2011; 34(5):230. PubMed ID: 21577027
[No Abstract] [Full Text] [Related]
27. Consolidation radiotherapy may improve outcomes in people with Hodgkin's disease achieving complete remission after combination chemotherapy.
Specht L
Cancer Treat Rev; 2004 Aug; 30(5):479-82. PubMed ID: 15245780
[No Abstract] [Full Text] [Related]
28. Marathon run under chemotherapy: is it possible?
Bernhörster M; Rosenhagen A; Vogt L; Thiel C; Jäger E; Banzer W
Onkologie; 2011; 34(5):259-61. PubMed ID: 21577032
[No Abstract] [Full Text] [Related]
29. Classical Hodgkin's lymphoma: past, present and future perspectives.
Eyre TA; King AJ; Collins GP
Br J Hosp Med (Lond); 2013 Nov; 74(11):612-8. PubMed ID: 24220522
[No Abstract] [Full Text] [Related]
30. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
31. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
32. Intrahepatic cholestasis and biliary cirrhosis associated with extrahepatic Hodgkin's disease.
Jansen PL; van der Lelie H
Neth J Med; 1994 Mar; 44(3):99-102. PubMed ID: 8202211
[TBL] [Abstract][Full Text] [Related]
33. HIV-related Hodgkin's disease with central nervous system involvement and association with Epstein-Barr virus.
Massarweh S; Udden MM; Shahab I; Kroll M; Sears DA; Lynch GR; Teh BS; Lu HH
Am J Hematol; 2003 Mar; 72(3):216-9. PubMed ID: 12605396
[TBL] [Abstract][Full Text] [Related]
34. Vanishing bile duct syndrome as a presentation of Hodgkin's lymphoma.
Fatima I; Mahadevia H; Madhusudhana S; Shrestha A
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772873
[TBL] [Abstract][Full Text] [Related]
35. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
[TBL] [Abstract][Full Text] [Related]
36. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
37. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy alone for early-stage Hodgkin's lymphoma.
Straus DJ
N Engl J Med; 2012 Feb; 366(5):470-1. PubMed ID: 22149920
[No Abstract] [Full Text] [Related]
39. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
40. [Primary treatment of early stage Hodgkin's disease].
Molnár Z; Esik O; Illés A
Orv Hetil; 2005 Jan; 146(2):57-61. PubMed ID: 15724953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
